🇺🇸 PD-1 Monoclonal Antibody in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 3
Most-reported reactions
- Bone Marrow Failure — 1 report (33.33%)
- Diarrhoea — 1 report (33.33%)
- Gastrointestinal Toxicity — 1 report (33.33%)
Other Oncology approved in United States
Frequently asked questions
Is PD-1 Monoclonal Antibody approved in United States?
PD-1 Monoclonal Antibody does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for PD-1 Monoclonal Antibody in United States?
Peking University People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.